What question did this study set out to answer?

Assess non-inferiority of sentinel lymph node biopsy alone versus completion axillary lymph node dissection in patients with breast cancer and sentinel node macrometastases.

February 19, 2026Clinical Cancer Research

Abstract GS2-02: Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial

View Full Paper

Ask AI

Bookmark

Authors

TRT. ReimerUniversity of Rostock ASA. StachsUniversity of Rostock KVK. VeselinovicUniversität Ulm

Discussion

Member takes

Implication

Prospective trial compares SLNB alone to cALND, showing no significant differences in patient outcomes.

Key Points

Assess non-inferiority of sentinel lymph node biopsy alone versus completion axillary lymph node dissection in patients with breast cancer and sentinel node macrometastases.
Conducted a prospective trial (INSEMA) in Germany and Austria from 2015 to 2019.
Randomized patients with sentinel node macrometastases to either SLNB alone or cALND.
Analyzed outcome differences in invasive disease-free survival and overall survival after median follow-up of 74.2 months.
No significant differences in invasive disease-free survival (HR 1.69, 95% CI: 0.98-2.94) between SLNB alone and cALND.
5-year invasive disease-free survival rates: 86.6% (SLNB) vs. 93.8% (cALND).
Patients undergoing SLNB alone showed lower lymphedema rates and improved arm mobility compared to cALND.

Cite This Study

Reimer et al. (2026) studied this question.

synapsesocial.com/papers/6996a8a9ecb39a600b3ef97d https://doi.org/10.1158/1557-3265.sabcs25-gs2-02

View Full Paper

Ask AI

Bookmark

Abstract GS2-02: Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract GS2-02: Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider